Alcon Completes Acquisition of LumiThera, Expands Footprint Into Retina Clinic and Dry AMD Space

GENEVA—Global eyecare leader Alcon (SIX/NYSE: ALC) announced that it has completed its acquisition of LumiThera, Inc., in a transaction that includes the company’s noninvasive Valeda photobiomodulation (PBM) device for the treatment of early and intermediate dry age-related macular degeneration (AMD), as well as a sub-set of late dry AMD (non-central involving geographic atrophy). Alcon first announced its intention to acquire LumiThera, a leader in light-based innovations for ophthalmology, in early July, as reported in VMAIL. The deal’s completion builds on Alcon’s presence in surgical retina, the company advised, expanding its footprint in the clinic and providing an entrance into the dry AMD market.